Related Experiment Video
Updated: Sep 14, 2025

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Pleckstrin-2 promotes the progression of colorectal cancer via YTHDF2-mediated TYMS mRNA stability
Qian Zhou1,2,3, Yanxia Li1,2,3, Xiaomei Li1,2
1Key Lab of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.
Abstract:
High expression of nucleotide synthetic enzyme thymidylate synthase (TYMS) is responsible for the resistance to fluorouracil (FU) treatment and worse survival in colorectal cancer (CRC). Herein, we revealed that pleckstrin-2 (PLEK2) cooperated with YTHDF2 to enhance TYMS mRNA stability in CRC via an m6A dependent manner. Silencing of PLEK2 led to the degradation of TYMS mRNA that suppressed DNA replication, which activated p53/p21 signaling and consequent inhibition of CRC cell proliferation via the cellular senescence. Additionally, PLEK2 is also required for CRC cell migration, invasion and stemness-like properties. PLEK2 inhibition is sufficient to ameliorate the progression of AOM/DSS-induced CRC. Together, our study identified PLEK2 as a key regulator for the progress of CRC via the regulation of TYMS expression, and demonstrated that PLEK2 is a novel therapeutic target for CRC.
Insights
Pleckstrin-2 (PLEK2) enhances thymidylate synthase (TYMS) mRNA stability in colorectal cancer (CRC), promoting tumor growth. Inhibiting PLEK2 triggers TYMS degradation, halting CRC cell proliferation and progression, suggesting PLEK2 as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- High thymidylate synthase (TYMS) expression correlates with fluorouracil (FU) resistance and poor survival in colorectal cancer (CRC).
- Understanding mechanisms regulating TYMS is crucial for developing effective CRC therapies.
Purpose of the Study:
- To investigate the role of pleckstrin-2 (PLEK2) in regulating TYMS expression and its impact on colorectal cancer progression.
- To identify PLEK2 as a potential therapeutic target for CRC treatment.
Main Methods:
- Investigated the interaction between PLEK2 and YTHDF2 in enhancing TYMS mRNA stability via an m6A-dependent manner.
- Utilized gene silencing techniques to assess the effects of PLEK2 depletion on CRC cells.
- Evaluated the impact of PLEK2 inhibition on CRC cell proliferation, migration, invasion, and stemness.
- Assessed the therapeutic efficacy of PLEK2 inhibition in an AOM/DSS-induced CRC mouse model.
Main Results:
- PLEK2 cooperates with YTHDF2 to stabilize TYMS mRNA in an m6A-dependent manner in CRC.
- Silencing PLEK2 leads to TYMS mRNA degradation, suppressing DNA replication and inducing p53/p21 signaling, resulting in cellular senescence and inhibited CRC cell proliferation.
- PLEK2 is essential for CRC cell migration, invasion, and stemness.
- PLEK2 inhibition ameliorates the progression of AOM/DSS-induced CRC.
Conclusions:
- PLEK2 is a key regulator of colorectal cancer progression through its control of TYMS expression.
- Targeting PLEK2 represents a novel therapeutic strategy for colorectal cancer.
Related Concept Videos
Abnormal Proliferation
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Destabilization of Microtubules
RNA Stability
Epigenetic Regulation

